Clinical Trials Browser

Completed × Neoplasms, Plasma Cell × carfilzomib × Clear all

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1/2 Completed

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04065789 2022-01-27

KyDaR

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Phase 2 Completed

50 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01279694 2016-04-13

CARMYSAP

Phase 1/2 Completed

Neoplasms, Plasma Cell